Hyperion Notified That FDA Will Not Meet the PDUFA Action Date for Ravicti(TM)
January 16, 2013 08:57 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) said that the U.S. Food and Drug Administration (FDA) has advised the Company not to expect a...
HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy
November 12, 2012 09:18 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the...
Hyperion Therapeutics Announces Third Quarter 2012 Operating Results
November 07, 2012 16:09 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (NasdaqGM:HPTX) today reported consolidated financial results for the third quarter of 2012.
According to...
Hyperion Therapeutics to Present at Upcoming Investor Conferences in November
November 05, 2012 14:49 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at two investor conferences in...
Hyperion Therapeutics to Host/Webcast Analyst and Investor Briefing at AASLD
October 17, 2012 16:30 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the company will host and webcast an analyst and investor briefing on...
Hyperion Therapeutics to Report Results of HALT-HE Study at AASLD Plenary Session
October 02, 2012 18:56 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the HALT-HE Study will be presented at the 63rd Annual...
Hyperion Therapeutics Announces Second Quarter 2012 Operating Results
September 06, 2012 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported consolidated financial results for the second quarter of 2012.
The company...
Hyperion Therapeutics Announces Extension of Action Date for Ravicti(TM) NDA to January 23, 2013
September 05, 2012 17:39 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that it has received a communication from the U.S. Food and Drug Administration...
Hyperion Therapeutics Appoints Daniel G. Welch to Board of Directors
August 28, 2012 16:00 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that it has named Daniel G. Welch to its Board of Directors. Mr. Welch currently...
Hyperion Therapeutics to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
August 21, 2012 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the BioCentury and Thomson Reuters 19th...